Leukemia | CHOP Research Institute
 

Leukemia

Cornerstone Blog

PA CURE Grant Fuels Childhood Leukemia Research at CHOP

Published on
Oct 16, 2024
PA CURE Grant Fuels Childhood Leukemia Research
The Pennsylvania Department of Health CURE grant will help researchers understand why treatment fails some children with B-ALL and helps others.
Cornerstone Blog

What Are the Genomic Drivers of Childhood T-ALL?

Published on
Sep 30, 2024
What Are the Genomic Drivers of Childhood T-ALL?
CHOP researchers uncovered 15 subtypes of T-cell acute lymphoblastic leukemia, which will help to predict outcomes and guide treatment.

Grupp Laboratory for Advanced Cancer Treatments

Grupp Laboratory for Advanced Cancer Treatments

The Grupp Lab develops new targeted cancer treatments and cell-based immunotherapies for leukemia and solid tumors, and aims to create advanced, less toxic treatments for children with high-risk cancers.

AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia

AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia

This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R).

22LL011; Epcoritamab in B-cell Neoplasms

22LL011; Epcoritamab in B-cell Neoplasms

CHOP in collaboration with AbbVie, is conducting a study for pediatric patients from 1 year of age to 25 years of age with relapsed or refractory aggressive mature B-cell neoplasms (including diffuse large B-cell lymphoma, Burkitt and Burkitt-like lymphoma/leukemia).

Cornerstone Blog

How Do CAR T-Cells Fare After One Decade?

Published on
Feb 3, 2022
How Do CAR T-Cells Fare After One Decade?
Two patients infused with CAR T-cell therapy one decade ago remain in remission with detectable levels of cancer-fighting cells.
Cornerstone Blog

CHOP Research Institute Highlights Emerging Leaders in Research

Published on
Nov 30, 2021
CHOP Research Institute Highlights Emerging Leaders in Research
The Emerging Innovators in Collaborative Research Program highlights non-faculty researchers.

AAML1921; Bosutinib for Chronic Myeloid Leukemia

The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).

Cornerstone Blog

How Does the Overexpression of MN1 Cause Acute Myeloid Leukemia?

Published on
May 19, 2021
How the Overexpression of MN1 Causes Acute Myeloid Leukemia
CHOP Researchers find the novel mechanistic link by which MNI causes acute myeloid leukemia.

Phase 1 Study Of Lentivirally Transduced T Cells Engineered To Contain Anti-CD123 In Subjects With Refractory Or Relapsed Acute Myeloid Leukemia

Phase 1 Study Of Lentivirally Transduced T Cells Engineered To Contain Anti-CD123 In Subjects With Refractory Or Relapsed Acute Myeloid Leukemia

Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia.